title: The impact of high-dose sodium selenite therapy on Bcl-2 expression in adult non-Hodgkin's lymphoma patients: correlation with response and survival.
abstract: The present study was undertaken to explore the effect of administration of high doses of sodium selenite on the expression of Bcl-2 in patients with non-Hodgkin's lymphoma (NHL). Fifty patients with newly diagnosed NHL were randomly divided into two groups. Group A-I received standard chemotherapy whereas group A-II received adjuvant sodium selenite 0.2 mg kg-1 day-1 for 30 days in addition to chemotherapy. Enzyme-linked immunosorbent assay was used to assess Bcl-2 at the time of diagnosis and after therapy in the two groups. Sodium selenite administration resulted in significant decline of Bcl-2 level after therapy in group A-II (8.6 +/- 6.9 ng/ml vs 3 6.9 +/- 7.9 ng/ml, P < 0.05). Also, complete response reached 60% in group A-II compared to 40% in group A-I. Significant increase in CD4/CD8 ratio was noticed in group A-II compared to group A-I after therapy (1.45 +/- 0.36 vs 1.10 +/- 0.28 p 0.04). Overall survival time in months was significantly longer in complete remission patients in group A-II (21.87 +/- 1.41) compared to group A-I (19.70 +/- 1.95) (p = 0.01). It is concluded that sodium selenite administration at the dosage and duration chosen acts as a down regulator of Bcl-2 and improves clinical outcome.
authors.affiliation: Clinical Hematology and Bone Marrow Transplantation Unit, Department of Internal Medicine, Ain Shams University Hospital, Cairo, Egypt.
authors.forename: Inas A
authors.initials: IA
authors.lastname: Asfour
authors.forename: Manal
authors.initials: M
authors.lastname: Fayek
authors.forename: Soha
authors.initials: S
authors.lastname: Raouf
authors.forename: Marize
authors.initials: M
authors.lastname: Soliman
authors.forename: Hany M
authors.initials: HM
authors.lastname: Hegab
authors.forename: Hosam
authors.initials: H
authors.lastname: El-Desoky
authors.forename: Rehab
authors.initials: R
authors.lastname: Saleh
authors.forename: Mohamed A R
authors.initials: MA
authors.lastname: Moussa
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D015536:Down-Regulation; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D018038:Sodium Selenite / Q000008:administration & dosage / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D018038:Sodium Selenite; D011241:Prednisone